Peter Kuponiyi, MD
Addiction Medicine · Egg Harbor Township, NJNPI 1285674010
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 563 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,531 and has fallen 53.5% since, to $712 in 2025. Among addiction medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 563 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$990
- Sunovion Pharmaceuticals Inc.$621
- Pfizer$601
- Amgen$508
- Novo Nordisk$474
- plus $4K from 49 others
What the payments were for
- Food & beverage$8,06098%
- Education$1622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,221 in reported general payments places this provider in the 95th percentile of 57 addiction medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArexvyRsvpref3 Antigen/As01e/Pf | 3,922 | $1,168,868 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 3,385 | $718,208 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 586 | $179,328 |
| EliquisApixaban | 405 | $178,422 |
| OzempicSemaglutide | 114 | $138,691 |
| JardianceEmpagliflozin | 149 | $97,870 |
| IngrezzaValbenazine Tosylate | 11 | $87,600 |
| FarxigaDapagliflozin Propanediol | 80 | $80,887 |
| RybelsusSemaglutide | 44 | $76,567 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $70,838 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 1,025 | $68,822 |
| JanuviaSitagliptin Phosphate | 68 | $68,622 |
| JanumetSitagliptin Phos/Metformin Hcl | 48 | $53,912 |
| TrulicityDulaglutide | 50 | $48,467 |
| LinzessLinaclotide | 75 | $42,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArexvy, Shingrix, Trelegy Ellipta, Twinrix, Anoro Ellipta | $451 | $2,004,6647,623 claims |
| PfizerAbrysvo, Eliquis | $601 | $357,751991 claims |
| Novo NordiskOzempic, Rybelsus | $474 | $215,258158 claims |
| MerckJanuvia, Janumet, Steglatro | $195 | $135,103137 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $990 | $102,497124 claims |
| Boehringer IngelheimJardiance | $324 | $97,870149 claims |
| AbbVieLinzess, Creon, Ubrelvy | $1,174 | $86,171101 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $240 | $61,70263 claims |
| NovartisEntresto | $75 | $40,30136 claims |
| Smith+NephewSantyl | $16 | $39,77917 claims |
| Johnson & JohnsonXarelto | $80 | $21,79033 claims |
| AmgenProlia | $508 | $19,55312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 addiction medicine providers in New Jersey.
Other addiction medicine in Egg Harbor Township
- Joseph RanieriSewell$28K
- Ruby KapadiaSaddle Brook$5K
- Richard HellanderCamden$3K
- Hayman RambaranParamus$2K
- Mohammed RahmanNeptune$2K
- David RussoBridgeton$1K
- Sailakshmi RamanujamToms River$1K
- Usman IjazClifton$943
- Lance GoobermanMerchantville$847
- Nola MahoneyHamilton$648
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.